Comparative Pharmacology
Head-to-head clinical analysis: QULIPTA versus UBROGEPANT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QULIPTA versus UBROGEPANT.
QULIPTA vs UBROGEPANT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QULIPTA (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It competitively blocks the binding of CGRP to its receptor, thereby inhibiting CGRP-mediated vasodilation and pain transmission involved in migraine pathophysiology.
Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It binds to CGRP receptors, blocking the vasodilatory and pro-inflammatory effects of CGRP, thereby aborting migraine attacks without causing vasoconstriction.
10 mg orally once daily
50 mg or 100 mg orally once daily as needed for acute treatment of migraine attacks; maximum daily dose: 200 mg. Not for prophylactic use.
None Documented
None Documented
Terminal elimination half-life is approximately 21 hours, supporting once-daily dosing.
Terminal elimination half-life is ~5-7 hours, supporting twice-daily dosing for migraine prevention.
Approximately 60% of the dose is excreted in feces (as unchanged drug and metabolites) and 40% in urine (primarily as metabolites, with <1% unchanged).
Primarily eliminated via biliary/fecal excretion (approximately 70% of dose recovered in feces) with ~30% renal excretion (mostly as unchanged drug).
Category C
Category C
CGRP Antagonist
CGRP Antagonist